Maridebart Cafraglutide

MariTide (maridebart cafraglutide) is Amgen's monthly-dosed obesity contender - a peptide-antibody conjugate that activates the GLP-1 receptor (the gut hormone target behind Wegovy and Zepbound) while simultaneously blocking the GIP receptor. In Phase 2 (NEJM, June 2025), mean weight loss at 52 weeks was 12-16% on the treatment-policy (intent-to-treat) estimand and reached ~20% on the efficacy estimand (on-drug, excluding dropouts) in obese patients without diabetes; up to 27% of patients in non-dose-escalated groups discontinued for GI side effects, a tolerability signal the Phase 3 program is designed to manage with titration [1]. Amgen has since launched a five-trial Phase 3 program (MARITIME) spanning a 12,800-patient cardiovascular outcomes study, heart failure with preserved ejection fraction, sleep apnea (two trials), and a Phase 2 in liver fat [3][4][5][6][9]. This node is a program-level entry; the specific trial ID NCT07229157 is a Phase 1 thorough-QT cardiac safety study - required regulatory hygiene before any obesity BLA (Biologics License Application) [7]. Amgen reported $33.4B in FY2024 revenue [8], easily funding the program, but the company has been punished by investors for arriving late to GLP-1; analyst consensus pegs the global obesity drug market at ~$100B+ by the early 2030s, and a 10-15% share for MariTide would translate to ~$10-15B in peak sales - the prize that justifies the spend.

Novel compound, first-in-class for the GLP-1 agonist plus GIP receptor antagonist combination. No FDA designations announced. The Phase 3 obesity program (MARITIME) launched in 2025 after the Phase 2 readout, and Amgen disclosed continued enrollment across all five Phase 3 studies in its FY2024 10-K filed in February 2025 [8]. NCT07229157 - the trial ID referenced in this node - is a Phase 1 thorough-QT (TQT) study evaluating placebo-corrected change in QTcF interval, the standard ICH E14 cardiac-repolarization assessment regulators require before approving any drug with meaningful systemic exposure [7]. Realistic timeline: first obesity-indication BLA (Biologics License Application - the FDA submission for biologics) filing in 2027-2028 if the lead Phase 3 trials read out cleanly. The cardiovascular outcomes trial (NCT07037433) accrues 3-point MACE events over years and likely won't read out until 2028-2029 - that label expansion is the long game, modeled on semaglutide's SELECT trial path [3]. Amgen has not publicly disclosed which specific dose/regimen from Phase 2 was advanced into the Phase 3 obesity arms; the Phase 2 tested multiple doses, and the dose selection is a key open question for the readout.

GLP-1 (glucagon-like peptide 1) is a gut hormone released after eating that does two useful things: tells your brain you're full and prompts your pancreas to release insulin. Semaglutide and tirzepatide both activate this receptor - that's the entire GLP-1 weight-loss category. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone, and the biology is messier. Lilly's tirzepatide ACTIVATES the GIP receptor and works very well. Amgen made the opposite bet: maridebart cafraglutide BLOCKS the GIP receptor. The rationale comes from human genetics - people carrying loss-of-function GIPR variants tend to have lower BMI - and from preclinical work in Nat Metab 2024 showing the antagonist conjugate produced superior weight loss versus GLP-1 agonism alone in obese mice and a Phase 1 cohort [2]. The format matters as much as the biology. Maridebart is a peptide fused to an antibody scaffold, which extends the half-life enough to enable monthly subcutaneous dosing rather than weekly. If the efficacy holds and patients prefer one injection a month over four, that's a real adherence and convenience edge that semaglutide and tirzepatide can't easily match without reformulation.

NCT07229157 is a Phase 1 placebo-controlled thorough-QT study (~60-100 healthy volunteers, the typical TQT footprint) measuring whether maridebart prolongs the QT interval - a cardiac repolarization signal that, when stretched, raises arrhythmia risk. Standard regulatory work, not a clinical efficacy readout [7]. The real clinical story lives in Phase 3. NCT07037433 randomizes 12,800 patients with established atherosclerotic disease plus overweight/obesity to maridebart or placebo, with 3-point MACE (cardiovascular death, MI, ischemic stroke) as the primary endpoint [3]. NCT07037459 enrolls 5,056 patients for the HFpEF indication, primary endpoint a composite of cardiovascular death plus heart failure events [4]. Two sleep apnea studies (NCT07225686 in patients on PAP therapy - positive airway pressure, i.e., CPAP machines; NCT07226765 in patients not on PAP) target change in apnea-hypopnea index (AHI - the number of breathing interruptions per hour of sleep) at week 52 [5][6]. NCT07441252 is a Phase 2 measuring liver fat reduction by MRI-PDFF (magnetic resonance imaging proton density fat fraction - a non-invasive liver-fat imaging measure) in patients with elevated liver fat [9]. Comparator across the obesity-adjacent indications is placebo, not head-to-head against tirzepatide - meaning Amgen will be selling on cross-trial comparison data when it comes time to win formulary fights, which is a structural disadvantage.

This drug has a 45% chance of eventually being approved, according to our model. Drugs at Phase 3 in this area are approved about 66% of the time historically; this estimate is lower because earlier trial results were weak and enrollment is smaller than typical for this stage. On the positive side, the trial has more secondary endpoints than usual and the sponsor has a strong record of getting drugs approved. The remaining factors are close to average for this stage, so they don't move the number much in either direction.

Efficacy: Phase 2 intent-to-treat weight loss was 12-16% with up to ~20% in patients who stayed on drug - the gap is the GI-tolerability tax, and discontinuation rates reached 27% in non-titrated dose groups, raising questions about whether real-world patients can stay on top doses long enough to see the efficacy-estimand benefit [1]. Safety: pancreatitis and gallbladder events are known class issues for GLP-1 drugs. GIPR antagonism is a new mechanism in humans at scale - long-term effects on bone density, glucose homeostasis, and energy expenditure regulation aren't fully characterized. The thorough-QT study itself is a low-probability failure point but a non-zero one. Competitive: Lilly is the existential threat. Retatrutide's Phase 2 weight loss numbers were better than maridebart's, and orforglipron offers oral dosing that no injectable can match for adherence. Novo's CagriSema disappointed but the company isn't out of the obesity race. Weight regain post-discontinuation: Phase 2 follow-up off-drug data is limited in what has been publicly disclosed, and durability of effect after stopping is a known weakness of the GLP-1 class generally. Commercial: even with approval, payer coverage remains the bottleneck for the entire GLP-1 category. Monthly dosing helps adherence but doesn't fix the affordability problem driving prior authorization denials and step-therapy requirements that gate access to Wegovy and Zepbound today.

Worth watching. The signal that matters is the Phase 3 obesity readout in 2027-2028: does the 12-16% intent-to-treat weight loss from Phase 2 hold up (or improve with titration), what's the discontinuation rate at therapeutic doses, and how does the weight-regain curve look in patients who stop dosing? Amgen's entire obesity strategy hinges on this molecule, and the stock has been punished since Phase 2 for being late and for tolerability concerns [8]. Check back after the next ADA or ObesityWeek conference for any updated Phase 2 follow-up or Phase 3 interim data, and at every Amgen earnings call for enrollment pace and any safety signals. The monthly dosing is the differentiator that could win even if peak efficacy lands a few points below tirzepatide - but only if Phase 3 data holds. The trial ID referenced in this node (NCT07229157) is procedural; the real catalysts are NCT07037433 and the other Phase 3 obesity arms. Amgen has the balance sheet to absorb a miss, but a miss would effectively concede the obesity market to Lilly and Novo for the rest of the decade - a market analyst consensus pegs at $100B+ by the early 2030s.

Amgen reported $33.4B in FY2024 revenue [8] and is the sole sponsor across all maridebart cafraglutide trials. MariTide is the company's primary entry into the obesity market and the most-watched asset in its pipeline. Two of Amgen's largest legacy franchises face biosimilar pressure this decade: Prolia/Xgeva (denosumab, ~$6.6B combined in FY2024) lost US exclusivity in 2025, and Repatha (~$2.2B in FY2024) faces patent expiry in the late 2020s [8]. The combined revenue at risk is in the high single-digit billions - roughly the scale MariTide would need to replace if it captures even a low-double-digit share of the projected obesity market.